Novo Nordisk's triple agonist is UBT251, a once-weekly injection that acts on three hormone receptors, GLP-1, GIP and glucagon, and it is in phase 2 (Novo, March 2026). Zenagamtide (also called amycretin), a second Novo medicine acting on the GLP-1 and amylin receptors, entered phase 3 in 2026 (Novo, August 2026). Both are investigational, and neither is registered in Singapore.
Availability in Singapore. Neither medicine is available in Singapore, even in a trial: neither UBT251 nor zenagamtide is registered with Singapore's Health Sciences Authority (HSA register), and no study of either lists a site here (ClinicalTrials.gov; ClinicalTrials.gov), so neither can be prescribed or supplied here. Both are still investigational. UBT251 is in phase 2 trials, with phase 3 trials registered in mainland China by United Biotechnology (ClinicalTrials.gov), and zenagamtide is in phase 3 trials (Novo, August 2026). Each is given only to people taking part in its trials, and anything offered for sale under either name is not what the trials studied.
Education only. This page is general education about medicines that are not registered in Singapore. It is not an advertisement or an offer. GetLean does not prescribe or supply UBT251 or zenagamtide, and nothing here recommends using either.
Triple agonist: a single molecule that acts at three hormone receptors. UBT251 acts at the receptors for GLP-1, GIP and glucagon (Novo, March 2026).
Which Novo Nordisk medicine is the triple agonist?
UBT251. Novo describes it as a long-acting synthetic peptide triple agonist, developed with United Biotechnology under an agreement signed in March 2025. United Biotechnology develops it in mainland China, Hong Kong, Macau and Taiwan, and Novo in the rest of the world (Novo, March 2026). Retatrutide also acts at GLP-1, GIP and glucagon receptors, but it is Lilly's (Jastreboff 2026); its status here is on the retatrutide page.
Novo's August 2026 report also lists an early project it calls "Triple": a phase 2 dose-finding trial in obesity, about 230 people for up to 39 weeks, expected to read out in the first quarter of 2027. The report does not say what molecule this is or whether it is related to UBT251 (Novo, August 2026).
What has UBT251 reported so far?
The figures announced so far come from a Chinese phase 2 trial in type 2 diabetes. It was randomised, double-blind and controlled with placebo and semaglutide 1 mg, and enrolled 211 people with a mean BMI of 29.1 (Novo, March 2026).
| Phase 2 trial, 24 weeks | UBT251 (2, 4 or 6 mg) | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Weight change | up to −9.8% | −4.8% | −1.4% |
| HbA1c reduction | up to 2.16 points | 1.77 points | 0.66 points |
Efficacy estimand, as if everyone stayed on treatment (Novo, March 2026). This is a trial in people with diabetes and a lower starting weight, so it cannot be set beside results from obesity trials. Individual results vary and are not guaranteed.
Novo's global phase 2 trial in people with overweight or obesity began in February 2026, and the registry estimates primary completion in January 2027 (ClinicalTrials.gov); Novo has said topline data are expected in 2027 (Novo, March 2026). A global phase 2 trial in type 2 diabetes is expected to read out at the end of 2027 (Novo, August 2026). Novo's release also refers to a recent positive phase 2 read-out in people with overweight or obesity without giving figures, so none are quoted here, and the registry lists a completed Chinese phase 2 study in overweight or obesity and registered Chinese phase 3 trials from United Biotechnology (ClinicalTrials.gov).
What is zenagamtide?
Zenagamtide, also known as amycretin, is a single peptide that acts on the GLP-1 and amylin receptors. Novo is developing it as a weekly injection and as a tablet, with separate programmes in type 2 diabetes and in overweight or obesity (Novo, June 2026). Amylin is a hormone the pancreas releases with insulin when food is eaten (Novo, June 2026); zenagamtide puts the GLP-1 and amylin actions in one molecule, where CagriSema combines two.
What has zenagamtide reported so far?
The figures announced so far come from a 36-week phase 2 dose-finding trial in 262 adults with type 2 diabetes. Average weight change ran from −4.35% at the lowest dose (0.4 mg) to −14.60% at the highest (40 mg), against −2.10% on placebo, in the on-treatment analysis without rescue medication. No plateau in weight loss had appeared by week 36 at the higher doses (Novo, June 2026). As with UBT251, this is a diabetes population, and individual results vary and are not guaranteed.
The phase 3 AMAZE programme began in 2026. The registry lists 15 phase 3 trials of zenagamtide, the largest planned to enrol 8,500 people, with the earliest estimated primary completion in June 2028 (ClinicalTrials.gov). Novo's report places the AMAZE 8 readout, a two-year comparison with semaglutide in people with overweight or obesity and type 2 diabetes, in the first half of 2029 (Novo, August 2026). No phase 3 results have been reported.
Are UBT251 or zenagamtide available in Singapore?
No. A full download of Singapore's register of therapeutic products, read on 9 October 2026, holds 5,511 records with approvals up to 8 July 2026, and none names zenagamtide, amycretin or UBT251 (HSA register). HSA's listing of approvals, updated 30 September 2026, has no entry for any of them (HSA approvals). No study of either medicine lists a site in Singapore (ClinicalTrials.gov; ClinicalTrials.gov). HSA's warning of 25 September 2026 applies to any unapproved injectable peptide still in development; it named retatrutide and cagrilintide (HSA 2026).
What do the trials say about stopping or keeping weight off?
Neither medicine has published results on stopping or maintenance. One phase 3 trial is built to ask the maintenance question for zenagamtide: AMAZE 12 assigns 606 adults who have reached their target dose to zenagamtide or placebo, with primary completion estimated for June 2028. No equivalent trial of UBT251 was found among 14 registered studies (ClinicalTrials.gov; ClinicalTrials.gov). When results arrive, the measure that matters for planning an exit is what happens to weight as the dose comes down, not only at the highest dose.
For semaglutide, the reference is the STEP 1 extension. The medication and the lifestyle support were stopped overnight at week 68, with no taper, and about two-thirds of the lost weight came back within a year (Wilding 2022).
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. While the medication keeps appetite quiet, daily WhatsApp coaching builds the eating pattern and the training habit that hold the result, and Dr Quek brings the dose down at the monthly reviews rather than stopping it overnight. After the taper, coaching and reviews can continue. Individual results vary, and a prescribed medicine should never be stopped or changed on one's own. How to come off GLP-1 in Singapore sets out the plan, with how a planned taper works and how much weight comes back after stopping in more detail. The status table of new weight-loss medicines puts both Novo medicines beside the rest.
For someone starting a GLP-1 for the first time
Neither medicine can be prescribed in Singapore, and both are still in trials: no zenagamtide phase 3 result has been reported, and UBT251's global phase 2 trials are still running. Medicines registered here for weight management already exist, and which one suits a person, if any does, is decided by the doctor who assesses them. Whether to do something now, or nothing, is a conversation to have with a doctor rather than a decision to make against a calendar that has not been published. Nothing on this page is a reason to act today either.
For someone already on a GLP-1 with another doctor
Neither medicine changes anything today, because neither can be prescribed here. Both are early: UBT251's global trials are in phase 2, and zenagamtide's results so far come from people with type 2 diabetes. Neither would remove the need to plan how a dose comes down. Which medicine and dose suit a person is the prescribing doctor's decision, and nothing here is a reason to stop or change a prescribed medicine.
Common questions
What is Novo Nordisk's triple agonist?
UBT251, a once-weekly injection that acts on the GLP-1, GIP and glucagon receptors, licensed from United Laboratories in March 2025 and now in phase 2 (Novo, March 2026). Retatrutide is also a triple agonist, but it is Eli Lilly's, not Novo's (Jastreboff 2026). Novo's August 2026 report also lists an early project it calls Triple, without naming the molecule (Novo, August 2026).
What are zenagamtide and amycretin?
They are the same medicine: zenagamtide is the name now used for amycretin, a peptide that acts on the GLP-1 and amylin receptors, in development as a weekly injection and as a tablet (Novo, June 2026). Its phase 3 programme began in 2026 (Novo, August 2026).
Are UBT251 or zenagamtide available in Singapore?
No. Neither appears on Singapore's register of therapeutic products or in HSA's listing of approvals, checked 9 October 2026, and no study of either lists a site here (HSA register; ClinicalTrials.gov). Both are investigational, and no date has been announced for either in this market.
What do the trials say about stopping or keeping weight off?
Neither medicine has published results on stopping or on maintenance. A phase 3 zenagamtide trial on maintaining weight loss, AMAZE 12, is registered with estimated primary completion in June 2028, and no equivalent trial of UBT251 was found (ClinicalTrials.gov).
Should I wait for a newer medicine before starting a GLP-1?
Nothing on this page supports a date, because none has been announced for this market. Medicines registered here for weight management already exist; which one suits a person, if any does, is decided by the doctor who assesses them, so whether to start now or not is a conversation with that doctor rather than a decision against a calendar.
I'm already on a GLP-1 with another doctor. Do UBT251 or zenagamtide change anything?
Not today: neither can be prescribed in Singapore, so neither changes what a current doctor can offer. Which medicine and dose suit someone is the prescribing doctor's decision, and a prescribed medicine should never be stopped or changed on one's own.